Tri-Modality therapy with I-125 brachytherapy, external beam radiation therapy, and short- or long-term hormone therapy for high-risk localized prostate cancer (TRIP): Study protocol for a phase III, multicenter, randomized, controlled trial

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Konaka, Hiroyuki ^a   Egawa, Shin ^b   Saito, Shiro ^c   Yorozu, Atsunori ^c   Takahashi, Hiroyuki ^b   Miyakoda, Keiko ^d   Fukushima, Masanori ^d   Dokiya, Takushi ^e   Yamanaka, Hidetoshi ^f   Stone, Nelson N ^g   Namiki, Mikio ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^d FOUNDATION FOR BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^e SAITAMA MEDICAL UNIVERSITY   (Japan)

^f Kurosawa Hospital   (Japan)

^g MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Biochemical progression free survival; Brachytherapy; External beam radiation therapy; Hormone therapy; Prostate cancer; Radiation therapy; Randomized controlled trial; Trimodality

Indexed keywords

IODINE 125; ANTIANDROGEN; GONADORELIN; RADIOACTIVE IODINE;

ARTICLE; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; DATA COLLECTION METHOD; DISEASE SPECIFIC SURVIVAL; EXTERNAL BEAM RADIOTHERAPY; HIGH RISK PATIENT; HUMAN; INFORMED CONSENT; LONG TERM CARE; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); SALVAGE THERAPY; SHORT COURSE THERAPY; STUDY DESIGN; ADULT; AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; INTENSITY MODULATED RADIATION THERAPY; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PHASE 3 CLINICAL TRIAL; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; ANDROGEN ANTAGONISTS; BRACHYTHERAPY; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84858719221     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-110     Document Type: Article

References (46)

1. Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR. The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 2004, 22(11):2141-2149. 10.1200/JCO.2004.10.062, 2997214, 15169800.
2. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, Tomaszewski JE, Renshaw AA, Kaplan I, Beard CJ, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280(11):969-974. 10.1001/jama.280.11.969, 9749478.
3. Bastian PJ, Gonzalgo ML, Aronson WJ, Terris MK, Kane CJ, Amling CL, Presti JC, Mangold LA, Humphreys E, Epstein JI, et al. Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. Cancer 2006, 107(6):1265-1272. 10.1002/cncr.22116, 16900523.
4. Dattoli M, Wallner K, True L, Cash J, Sorace R. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer 2007, 110(3):551-555. 10.1002/cncr.22810, 17577217.
5. Sylvester JE, Grimm PD, Blasko JC, Millar J, Orio PF, Skoglund S, Galbreath RW, Merrick G. 15-Year biochemical relapse free survival in clinical Stage T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy; Seattle experience. International journal of radiation oncology, biology, physics 2007, 67(1):57-64. 10.1016/j.ijrobp.2006.07.1382, 17084544.
6. Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MJ, Roach M, Shinohara K, Fearn PA, Kattan MW, Stock RG. Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. International journal of radiation oncology, biology, physics 2009, 73(2):341-346. 10.1016/j.ijrobp.2008.04.038, 18597953.
7. Nag S, Beyer D, Friedland J, Grimm P, Nath R. American Brachytherapy Society (ABS) recommendations for transperineal permanent brachytherapy of prostate cancer. International journal of radiation oncology, biology, physics 1999, 44(4):789-799. 10.1016/S0360-3016(99)00069-3, 10386635.
8. Zietman AL, Shipley WU. Androgen deprivation and radiation therapy in prostate cancer: the evolving case for combination therapy. International journal of radiation oncology, biology, physics 1997, 37(2):245-246. 10.1016/S0360-3016(97)00122-3, 9069292.
9. Joon DL, Hasegawa M, Sikes C, Khoo VS, Terry NH, Zagars GK, Meistrich ML, Pollack A. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. International journal of radiation oncology, biology, physics 1997, 38(5):1071-1077. 10.1016/S0360-3016(97)00303-9, 9276374.
10. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360(9327):103-106. 10.1016/S0140-6736(02)09408-4, 12126818.
11. Horwitz EM, Bae K, Hanks GE, Porter A, Grignon DJ, Brereton HD, Venkatesan V, Lawton CA, Rosenthal SA, Sandler HM, et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J Clin Oncol 2008, 26(15):2497-2504. 10.1200/JCO.2007.14.9021, 18413638.
12. Bolla M, de Reijke TM, Van Tienhoven G, Van den Bergh AC, Oddens J, Poortmans PM, Gez E, Kil P, Akdas A, Soete G, et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med 2009, 360(24):2516-2527. 10.1056/NEJMoa0810095, 19516032.
13. D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007, 25(17):2420-2425. 10.1200/JCO.2006.09.3369, 17557956.
14. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, Lin X, Greenfield TK, Litwin MS, Saigal CS, et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358(12):1250-1261. 10.1056/NEJMoa074311, 18354103.
15. Saito S, Nagata H, Kosugi M, Toya K, Yorozu A. Brachytherapy with permanent seed implantation. Int J Clin Oncol 2007, 12(6):395-407. 10.1007/s10147-007-0710-x, 18071858.
16. Nath R, Bice WS, Butler WM, Chen Z, Meigooni AS, Narayana V, Rivard MJ, Yu Y. AAPM recommendations on dose prescription and reporting methods for permanent interstitial brachytherapy for prostate cancer: report of Task Group 137. Med Phys 2009, 36(11):5310-5322. 10.1118/1.3246613, 2776817, 19994539.
17. Stone NN, Stock RG. Prostate brachytherapy: treatment strategies. J Urol 1999, 162(2):421-426. 10.1016/S0022-5347(05)68574-6, 10411050.
18. Raben A, Chen H, Grebler A, Geltzeiler J, Geltzeiler M, Keselman I, Litvin S, Sim S, Hanlon A, Yang J. Prostate seed implantation using 3D-computer assisted intraoperative planning vs. a standard look-up nomogram: Improved target conformality with reduction in urethral and rectal wall dose. International journal of radiation oncology, biology, physics 2004, 60(5):1631-1638. 10.1016/j.ijrobp.2004.08.003, 15590195.
19. Kestin L, Goldstein N, Vicini F, Yan D, Korman H, Martinez A. Treatment of prostate cancer with radiotherapy: should the entire seminal vesicles be included in the clinical target volume?. International journal of radiation oncology, biology, physics 2002, 54(3):686-697. 10.1016/S0360-3016(02)03011-0, 12377319.
20. Stock RG, Ho A, Cesaretti JA, Stone NN. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. International journal of radiation oncology, biology, physics 2006, 66(2):389-394. 10.1016/j.ijrobp.2006.05.072, 16965991.
21. Grossfeld GD, Latini DM, Lubeck DP, Mehta SS, Carroll PR. Predicting recurrence after radical prostatectomy for patients with high risk prostate cancer. J Urol 2003, 169(1):157-163. 10.1016/S0022-5347(05)64058-X, 12478126.
22. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997, 277(18):1445-1451. 10.1001/jama.1997.03540420041027, 9145716.
23. Naito S, Kuroiwa K, Kinukawa N, Goto K, Koga H, Ogawa O, Murai M, Shiraishi T. Validation of Partin tables and development of a preoperative nomogram for Japanese patients with clinically localized prostate cancer using 2005 International Society of Urological Pathology consensus on Gleason grading: data from the Clinicopathological Research Group for Localized Prostate Cancer. J Urol 2008, 180(3):904-909. discussion 909-910, 10.1016/j.juro.2008.05.047, 18635221.
24. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, Wein A. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995, 154(1):131-138. 10.1016/S0022-5347(01)67248-3, 7539857.
25. Laverdiere J, Gomez JL, Cusan L, Suburu ER, Diamond P, Lemay M, Candas B, Fortin A, Labrie F. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. International journal of radiation oncology, biology, physics 1997, 37(2):247-252. 10.1016/S0360-3016(96)00513-5, 9069293.
26. van den Ouden D, Hop WC, Schroder FH. Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 1998, 160(4):1392-1397. 10.1016/S0022-5347(01)62546-1, 9751362.
27. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International journal of radiation oncology, biology, physics 2002, 53(5):1097-1105. 10.1016/S0360-3016(02)02829-8, 12128107.
28. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Miller DW, Adams JA, Shipley WU. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005, 294(10):1233-1239. 10.1001/jama.294.10.1233, 16160131.
29. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001, 166(3):876-881. 10.1016/S0022-5347(05)65855-7, 11490237.
30. Stock RG, Stone NN, Cesaretti JA, Rosenstein BS. Biologically effective dose values for prostate brachytherapy: effects on PSA failure and posttreatment biopsy results. International journal of radiation oncology, biology, physics 2006, 64(2):527-533. 10.1016/j.ijrobp.2005.07.981, 16242258.
31. Stone NN, Stock RG, Cesaretti JA, Unger P. Local control following permanent prostate brachytherapy: effect of high biologically effective dose on biopsy results and oncologic outcomes. International journal of radiation oncology, biology, physics 2010, 76(2):355-360. 10.1016/j.ijrobp.2009.01.078, 19632069.
32. Widmark A, Klepp O, Solberg A, Damber JE, Angelsen A, Fransson P, Lund JA, Tasdemir I, Hoyer M, Wiklund F, et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009, 373(9660):301-308. 10.1016/S0140-6736(08)61815-2, 19091394.
33. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365(9472):1687-1717. Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
34. Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D, Messing E, Forman J, Chin J, Swanson G, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006, 296(19):2329-2335. 10.1001/jama.296.19.2329, 17105795.
35. Van der Kwast TH, Bolla M, Van Poppel H, Van Cangh P, Vekemans K, Da Pozzo L, Bosset JF, Kurth KH, Schroder FH, Collette L. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007, 25(27):4178-4186. 10.1200/JCO.2006.10.4067, 17878474.
36. Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Storkel S, Willich N, Semjonow A, Souchon R, Stockle M, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009, 27(18):2924-2930. 10.1200/JCO.2008.18.9563, 19433689.
37. Albert M, Tempany CM, Schultz D, Chen MH, Cormack RA, Kumar S, Hurwitz MD, Beard C, Tuncali K, O'Leary M, et al. Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy. Cancer 2003, 98(5):949-954. 10.1002/cncr.11595, 12942561.
38. Ghaly M, Wallner K, Merrick G, True L, Sutlief S, Cavanagh W, Butler W. The effect of supplemental beam radiation on prostate brachytherapy-related morbidity: morbidity outcomes from two prospective randomized multicenter trials. International journal of radiation oncology, biology, physics 2003, 55(5):1288-1293. 10.1016/S0360-3016(02)04527-3, 12654439.
39. Sarosdy MF. Urinary and rectal complications of contemporary permanent transperineal brachytherapy for prostate carcinoma with or without external beam radiation therapy. Cancer 2004, 101(4):754-760. 10.1002/cncr.20446, 15305406.
40. Singh AM, Gagnon G, Collins B, Niroomand-Rad A, McRae D, Zhang Y, Regan J, Lynch J, Dritschilo A. Combined external beam radiotherapy and Pd-103 brachytherapy boost improves biochemical failure free survival in patients with clinically localized prostate cancer: results of a matched pair analysis. Prostate 2005, 62(1):54-60. 10.1002/pros.20118, 15389809.
41. Ragde H, Korb LJ, Elgamal AA, Grado GL, Nadir BS. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up. Cancer 2000, 89(1):135-141. 10.1002/1097-0142(20000701)89:1<135::AID-CNCR18>3.0.CO;2-#, 10897010.
42. Rosenthal SA, Linstadt DE, Leibenhaut MH, Andras EJ, Brooks CP, Stickney DR, Chang GC, Wolkov HB, Gilbert RM. Flutamide-associated liver toxicity during treatment with total androgen suppression and radiation therapy for prostate cancer. Radiology 1996, 199(2):451-455.
43. Bria E, Cuppone F, Giannarelli D, Milella M, Ruggeri EM, Sperduti I, Pinnaro P, Terzoli E, Cognetti F, Carlini P. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials. Cancer 2009, 115(15):3446-3456. 10.1002/cncr.24392, 19484790.
44. Lee LN, Stock RG, Stone NN. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. International journal of radiation oncology, biology, physics 2002, 52(2):444-452. 10.1016/S0360-3016(01)02598-6, 11872291.
45. Coblentz TR, Bissonette EA, Williams KR, Theodorescu D. Multimodality radiotherapy and androgen ablation in the treatment of clinically localized prostate cancer: early results in high risk patients. Prostate Cancer Prostatic Dis 2002, 5(3):219-225. 10.1038/sj.pcan.4500585, 12496985.
46. Merrick GS, Butler WM, Wallner KE, Galbreath RW, Allen ZA, Adamovich E, Lief J. Androgen deprivation therapy does not impact cause-specific or overall survival in high-risk prostate cancer managed with brachytherapy and supplemental external beam. International journal of radiation oncology, biology, physics 2007, 68(1):34-40. 10.1016/j.ijrobp.2006.11.046, 17289288.